Evidence map›Paper›PMID 39894227›Full record

ArticleThe Journal of allergy and clinical immunology2025

BNT162b2 COVID-19 vaccination elicits the expansion of CD16

Claudia De Pasquale, Fabiana Drommi, Alessia Calabrò, Cirino Botta, Giacomo Sidoti Migliore, Paolo Carrega, Grazia Vento, Amirhossein Gaeini, Gaetana Pezzino, José Freni and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of allergy and clinical immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Claudia De PasqualeLaboratory of Immunology and Biotherapy, Department Human Pathology "G. Barresi", University of Messina, Messina, Italy.
Fabiana DrommiLaboratory of Immunology and Biotherapy, Department Human Pathology "G. Barresi", University of Messina, Messina, Italy.
Alessia CalabròLaboratory of Immunology and Biotherapy, Department Human Pathology "G. Barresi", University of Messina, Messina, Italy.
Cirino BottaDepartment of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties "G. D'Alessandro", University of Palermo, Palermo, Italy.
Giacomo Sidoti MiglioreTranslational Immunobiology Unit, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md.
Paolo CarregaLaboratory of Immunology and Biotherapy, Department Human Pathology "G. Barresi", University of Messina, Messina, Italy.
Grazia VentoDepartment of Experimental Medicine, University of Genoa, Genova, Italy.
Amirhossein GaeiniDepartment of Experimental Medicine, University of Genoa, Genova, Italy.
Gaetana PezzinoLaboratory of Immunology and Biotherapy, Department Human Pathology "G. Barresi", University of Messina, Messina, Italy.
José FreniLaboratory of Immunology and Biotherapy, Department Human Pathology "G. Barresi", University of Messina, Messina, Italy.
Irene BonaccorsiLaboratory of Immunology and Biotherapy, Department Human Pathology "G. Barresi", University of Messina, Messina, Italy.
Massimo VitaleUnit of Experimental Pathology and Immunology, Istituto di Ricovero e Cura a Carattere Scientifico Ospedale Policlinico San Martino, Genova, Italy.
Gilberto FilaciBiotherapy Unit, Istituto di Ricovero e Cura a Carattere Scientifico Ospedale Policlinico San Martino, Genova, Italy; Department of Internal Medicine, University of Genoa, Genova, Italy.
Daniela FenoglioBiotherapy Unit, Istituto di Ricovero e Cura a Carattere Scientifico Ospedale Policlinico San Martino, Genova, Italy; Department of Internal Medicine, University of Genoa, Genova, Italy.
Raffaella IemmoLaboratory of Immunology and Biotherapy, Department Human Pathology "G. Barresi", University of Messina, Messina, Italy.
Gregorio CostaLaboratory of Immunology and Biotherapy, Department Human Pathology "G. Barresi", University of Messina, Messina, Italy; Clinical Pathology Unit, University Hospital Policlinico G. Martino, Messina, Italy.
Riccardo CavaliereLaboratory of Immunology and Biotherapy, Department Human Pathology "G. Barresi", University of Messina, Messina, Italy; Clinical Pathology Unit, University Hospital Policlinico G. Martino, Messina, Italy.
Guido FerlazzoDepartment of Experimental Medicine, University of Genoa, Genova, Italy; Unit of Experimental Pathology and Immunology, Istituto di Ricovero e Cura a Carattere Scientifico Ospedale Policlinico San Martino, Genova, Italy. Electronic address: guido.ferlazzo@unige.it.
Stefania CampanaLaboratory of Immunology and Biotherapy, Department Human Pathology "G. Barresi", University of Messina, Messina, Italy.

Funding

Origin and maturation of protective memory B cell responses against pathogenic viruses in natural infections and upon vaccination.ZIAAI001342 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI BONSIGNORI, MATTIA · 2021 to 2025
$7.0M
Intramural NIH HHS ZIA AI001342
6 · The paper itself

Abstract

backgroundThe Pfizer-BioNtech vaccine, also known as BNT162b2, was developed using a novel technology based on mRNA and protects against coronavirus disease 2019 (COVID-19) via induction of specific antibody and T-cell responses. Much less is known about the broader effects of this new class of vaccines on unconventional cellular components of the immune system.

objectivesWe aimed to characterize a subset of unconventional T cells emerging following BNT162b2 mRNA vaccination.

methodsPeripheral blood from a total of 30 human healthy individuals who received 2 doses of the BNT162b2 mRNA vaccine was collected for the analysis of T-cell compartment by using multiparametric flow cytometry and single-cell transcriptome analyses.

resultsIn the peripheral blood of individuals undergoing BNT162b2 vaccination, we observed a sizable fraction of CD8

conclusionsThese data indicate that BNT162b2 COVID-19 vaccination provides an additional large fraction of antibody-dependent cellular cytotoxicity (ADCC)-capable effector cells, endowed with innate functions and therefore able to potentially counteract a much wider array of diseases, including cancer.

Indexed as

CD8-Positive T-LymphocytesCOVID-19COVID-19 VaccinesKiller Cells, NaturalReceptors, IgGSARS-CoV-2AdultBNT162 VaccineFemaleGPI-Linked ProteinsHumansMaleMiddle AgedVaccinationBNT162 VaccineCOVID-19 VaccinesFCGR3B protein, humanGPI-Linked ProteinsReceptors, IgGADCCBNT162b2 mRNA vaccineCD16/FcγRIIIAhumaninnate-like T cellsNK cellsspike-specific CD8(+) T cells

Identifiers

PMID39894227
PMCPMC12145267

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.